Axsome Therapeutics Quarterly Income Statements Chart
Quarterly
|
Annual
Axsome Therapeutics Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| revenues: | |||||||||||||||||||||||||||||||||||||
| product sales | 148,959,000 | 120,358,000 | 117,325,000 | 103,736,000 | 86,520,000 | 74,096,000 | 70,747,000 | 57,127,000 | 46,017,000 | 28,569,000 | 24,371,528 | 16,845,792 | 8,819,786 | ||||||||||||||||||||||||
| royalty revenue | 1,083,000 | 1,105,000 | 643,750 | 1,026,000 | 646,000 | 903,000 | 783,000 | 667,000 | 683,000 | 272,000 | |||||||||||||||||||||||||||
| total revenues | 150,042,000 | 121,463,000 | 118,766,000 | 104,762,000 | 87,166,000 | 74,999,000 | 71,530,000 | 57,794,000 | 46,700,000 | 94,576,000 | |||||||||||||||||||||||||||
| yoy | 72.13% | 61.95% | 66.04% | 81.27% | 86.65% | -20.70% | |||||||||||||||||||||||||||||||
| qoq | 23.53% | 2.27% | 13.37% | 20.19% | 16.22% | 4.85% | 23.77% | 23.76% | -50.62% | ||||||||||||||||||||||||||||
| operating expenses: | |||||||||||||||||||||||||||||||||||||
| cost of revenue | 13,448,000 | 9,789,000 | 10,514,000 | 8,437,000 | 8,055,000 | 6,297,000 | 7,378,000 | 6,532,000 | 4,599,000 | 7,556,000 | |||||||||||||||||||||||||||
| gross profit | 136,594,000 | 111,674,000 | 108,252,000 | 96,325,000 | 79,111,000 | 68,702,000 | 64,152,000 | 51,262,000 | 42,101,000 | 87,020,000 | |||||||||||||||||||||||||||
| yoy | 72.66% | 62.55% | 68.74% | 87.91% | 87.91% | -21.05% | |||||||||||||||||||||||||||||||
| qoq | 22.31% | 3.16% | 12.38% | 21.76% | 15.15% | 7.09% | 25.15% | 21.76% | -51.62% | ||||||||||||||||||||||||||||
| gross margin % | 91.04% | 91.94% | 91.15% | 91.95% | 90.76% | 91.60% | 89.69% | 88.70% | 90.15% | 92.01% | |||||||||||||||||||||||||||
| research and development | 49,541,000 | 44,785,000 | 55,006,000 | 45,388,000 | 49,853,000 | 36,830,000 | 30,803,000 | 28,767,000 | 20,581,000 | 17,793,000 | 14,693,083 | 14,877,021 | 15,792,202 | 12,585,141 | 13,781,453 | 13,180,258 | 14,503,326 | 16,595,689 | 17,384,729 | 14,795,493 | 19,205,271 | 15,835,573 | 11,003,142 | 7,603,081 | 7,151,232 | 6,040,780 | 5,550,532 | 4,752,511 | 4,493,910 | 4,471,126 | 5,007,361 | 5,985,219 | 5,806,771 | 5,568,777 | 5,298,060 | 4,526,252 | |
| selling, general and administrative | 130,280,000 | 120,787,000 | 113,271,000 | 95,564,000 | 103,554,000 | 98,970,000 | 86,809,000 | 83,188,000 | 78,935,000 | 74,191,000 | 61,497,347 | 40,892,443 | 31,160,140 | ||||||||||||||||||||||||
| gain in fair value of contingent consideration | -8,102,000 | 1,512,000 | 4,284,750 | 16,391,000 | -1,412,000 | 1,427,750 | -180,000 | 6,053,000 | -162,000 | -225,530 | -42,120 | -860,000 | |||||||||||||||||||||||||
| intangible asset amortization | 1,589,000 | 1,572,000 | 1,607,000 | 1,606,000 | 1,590,000 | 1,589,000 | 1,607,000 | 1,607,000 | 1,589,000 | 1,572,000 | 1,606,789 | 1,606,789 | 925,650 | ||||||||||||||||||||||||
| total operating expenses | 186,756,000 | 178,445,000 | 191,383,000 | 167,386,000 | 165,212,000 | 142,274,000 | 169,804,000 | 119,914,000 | 111,757,000 | 100,950,000 | 84,288,497 | 59,257,964 | 48,000,828 | 38,288,872 | 32,608,040 | 33,407,142 | 30,847,687 | 27,844,061 | 27,744,236 | 21,126,801 | 24,428,170 | 18,947,235 | 13,448,219 | 10,421,473 | 9,450,315 | 8,243,459 | 7,989,593 | 7,163,210 | 6,444,120 | 6,297,416 | 6,750,738 | 7,672,033 | 7,625,560 | 7,207,803 | 6,827,280 | 5,882,865 | |
| income from operations | -36,714,000 | -56,982,000 | -72,617,000 | -62,624,000 | -78,046,000 | -67,275,000 | -98,274,000 | -62,120,000 | -65,057,000 | -6,374,000 | -59,916,969 | -42,412,172 | -39,181,042 | -38,288,872 | -32,608,040 | -33,407,142 | -30,847,687 | -27,844,061 | -27,744,236 | -21,126,801 | -24,428,170 | -18,947,235 | -13,448,219 | -10,421,473 | -9,450,315 | -8,243,459 | -7,989,593 | -7,163,210 | -6,444,120 | -6,297,416 | -6,750,738 | -7,672,033 | -7,625,560 | -7,207,803 | -6,827,280 | -5,882,865 | |
| yoy | -52.96% | -15.30% | -26.11% | 0.81% | 19.97% | 955.46% | 64.02% | 46.47% | 66.04% | -83.35% | 83.75% | 26.96% | 27.01% | 37.51% | 17.53% | 58.13% | 26.28% | 46.96% | 106.30% | 102.72% | 158.49% | 129.85% | 68.32% | 45.49% | 46.65% | 30.90% | 18.35% | -6.63% | -15.49% | -12.63% | -1.12% | 30.41% | |||||
| qoq | -35.57% | -21.53% | 15.96% | -19.76% | 16.01% | -31.54% | 58.20% | -4.51% | 920.66% | -89.36% | 41.27% | 8.25% | 2.33% | 17.42% | -2.39% | 8.30% | 10.79% | 0.36% | 31.32% | -13.51% | 28.93% | 40.89% | 29.04% | 10.28% | 14.64% | 3.18% | 11.54% | 11.16% | 2.33% | -6.72% | -12.01% | 0.61% | 5.80% | 5.57% | 16.05% | ||
| operating margin % | -24.47% | -46.91% | -61.14% | -59.78% | -89.54% | -89.70% | -137.39% | -107.49% | -139.31% | -6.74% | |||||||||||||||||||||||||||
| interest expense | -1,834,000 | -2,431,000 | -2,210,000 | -1,978,000 | -1,299,000 | -1,082,000 | -702,000 | -757,000 | -2,730,000 | -2,264,000 | -1,322,643 | -2,411,040 | |||||||||||||||||||||||||
| loss on debt extinguishment | -10,385,000 | ||||||||||||||||||||||||||||||||||||
| income before income taxes | -48,933,000 | -59,413,000 | -74,827,000 | -64,602,000 | -79,345,000 | -68,357,000 | -98,976,000 | -62,877,000 | -67,787,000 | ||||||||||||||||||||||||||||
| income tax benefit | 960,000 | -321,250 | 678,000 | 617,000 | |||||||||||||||||||||||||||||||||
| net income | -47,973,000 | -59,413,000 | -74,912,000 | -64,602,000 | -79,345,000 | -68,357,000 | -98,651,000 | -62,199,000 | -67,170,000 | -11,218,000 | -61,239,612 | -44,823,212 | -41,438,516 | -39,632,311 | -33,976,136 | -34,882,677 | -32,284,209 | -29,259,970 | -29,164,647 | -22,924,815 | -24,806,984 | -19,135,612 | -13,762,214 | -10,640,376 | -9,597,015 | -8,281,974 | -8,280,916 | -4,805,559 | -7,430,501 | -6,433,536 | -7,084,316 | -7,995,039 | -7,328,938 | -7,194,584 | -6,812,190 | -5,865,941 | |
| yoy | -39.54% | -13.08% | -24.06% | 3.86% | 18.13% | 509.35% | 61.09% | 38.77% | 62.10% | -71.69% | 80.24% | 28.50% | 28.36% | 35.45% | 16.50% | 52.16% | 30.14% | 52.91% | 111.92% | 115.45% | 158.49% | 131.05% | 66.19% | 121.42% | 29.16% | 28.73% | 16.89% | -39.89% | 1.39% | -10.58% | 3.99% | 36.30% | |||||
| qoq | -19.26% | -20.69% | 15.96% | -18.58% | 16.07% | -30.71% | 58.61% | -7.40% | 498.77% | -81.68% | 36.62% | 8.17% | 4.56% | 16.65% | -2.60% | 8.05% | 10.34% | 0.33% | 27.22% | -7.59% | 29.64% | 39.04% | 29.34% | 10.87% | 15.88% | 0.01% | 72.32% | -35.33% | 15.50% | -9.19% | -11.39% | 9.09% | 1.87% | 5.61% | 16.13% | ||
| net income margin % | -31.97% | -48.91% | -63.08% | -61.67% | -91.03% | -91.14% | -137.92% | -107.62% | -143.83% | -11.86% | |||||||||||||||||||||||||||
| net income per common share, basic and diluted | -970 | -1,220 | -1,540 | -1,340 | -1,670 | -1,440 | -2,130 | -1,320 | -1,540 | -260 | -1.43 | -1.07 | -1.06 | -1.03 | -0.9 | -0.93 | -0.86 | -0.78 | -0.79 | -0.61 | -0.72 | -0.56 | -0.41 | -0.32 | -0.32 | -0.31 | -0.32 | -0.19 | -0.243 | -0.27 | -0.3 | -0.41 | -0.26 | -0.38 | -0.36 | -0.31 | |
| weighted-average common shares outstanding, basic and diluted | 49,442,001,000 | 48,871,163,000 | 47,914,253,000 | 48,140,519,000 | 47,573,229,000 | 47,393,563,000 | 45,425,212,000 | 47,117,196,000 | 43,669,820,000 | 43,523,631,000 | 40,655,941 | 41,704,362 | 39,081,100 | 38,323,167 | 37,618,599 | 37,680,966 | 37,595,069 | 37,429,450 | 37,206,928 | 37,311,726 | 34,020,257 | 34,445,489 | 33,801,749 | 33,052,468 | 26,883,656 | 26,325,904 | 25,791,177 | 25,501,188 | 23,634,040 | 23,595,702 | 19,537,897 | 19,149,906 | 19,149,417 | 19,149,417 | |||
| income tax expense | |||||||||||||||||||||||||||||||||||||
| license revenue | 65,735,000 | ||||||||||||||||||||||||||||||||||||
| loss in fair value of contingent consideration | 2,160,000 | ||||||||||||||||||||||||||||||||||||
| income before benefit from income taxes | -8,638,000 | ||||||||||||||||||||||||||||||||||||
| benefit from income taxes | -2,580,000 | ||||||||||||||||||||||||||||||||||||
| cost of product sales | 2,290,928 | 1,923,831 | 982,836 | ||||||||||||||||||||||||||||||||||
| interest income | -2,257,474 | -1,343,439 | -272,962.25 | -551,002 | |||||||||||||||||||||||||||||||||
| general and administrative | 25,703,731 | 18,826,587 | 20,226,884 | 16,344,361 | 11,248,372 | 10,359,507 | 6,331,308 | 5,222,899 | 3,111,662 | 2,445,077 | 2,818,392 | 2,299,083 | 2,202,679 | 2,439,061 | 2,410,699 | 1,950,210 | 1,826,290 | 1,743,377 | 1,686,814 | 1,818,789 | 1,639,026 | 1,529,220 | 1,356,613 | ||||||||||||||
| balance at december 31, 2020 | 37,374,088 | ||||||||||||||||||||||||||||||||||||
| stock-based compensation | |||||||||||||||||||||||||||||||||||||
| issuance of common stock upon exercise of options | 94,000 | ||||||||||||||||||||||||||||||||||||
| issuance of common stock upon vesting of rsus | 1,917 | ||||||||||||||||||||||||||||||||||||
| issuance of common stock upon financing | 93,877 | ||||||||||||||||||||||||||||||||||||
| balance at march 31, 2021 | 37,563,882 | ||||||||||||||||||||||||||||||||||||
| balance at december 31, 2021 | 37,816,794 | ||||||||||||||||||||||||||||||||||||
| shares tendered for withholding taxes | |||||||||||||||||||||||||||||||||||||
| balance at march 31, 2022 | 38,883,445 | ||||||||||||||||||||||||||||||||||||
| interest and amortization of debt discount income | -1,081,991.5 | -1,475,535 | -1,436,522 | -1,415,909 | |||||||||||||||||||||||||||||||||
| loss on extinguishment of debt | -1,247,012 | ||||||||||||||||||||||||||||||||||||
| | |||||||||||||||||||||||||||||||||||||
| tax credit | 139,448 | 217,418 | 207,114 | ||||||||||||||||||||||||||||||||||
| interest and amortization of debt discount | -215,180.75 | -327,825 | -313,995 | -218,903 | -219,651.25 | -270,933 | -292,323 | -315,349 | |||||||||||||||||||||||||||||
| change in fair value of warrant liability | 102,000 | 15,000 | 1,000 | 2,673,000 | |||||||||||||||||||||||||||||||||
| interest and amortization of debt discount/premium income | -249,954.5 | -343,234 | -333,578 | -323,006 | 16,924 | ||||||||||||||||||||||||||||||||
| interest and other income | 11,308.25 | 13,219 | 15,090 | ||||||||||||||||||||||||||||||||||
| change in fair value of embedded derivative liabilities |
We provide you with 20 years income statements for Axsome Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Axsome Therapeutics stock. Explore the full financial landscape of Axsome Therapeutics stock with our expertly curated income statements.
The information provided in this report about Axsome Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.